Ersatta: Phase Ib data

A double-blind, placebo-controlled, U.S. Phase Ib trial in 30 Type I diabetics showed that multiple doses of 0.3, 1 and 3.3 mg subcutaneous Ersatta were well tolerated with no serious adverse events r...